Skip to main content
PMC home page
AAPS PharmSciTech logoLink to AAPS PharmSciTech
. 2005 Dec 7;6(4):E618–E625. doi: 10.1208/pt060476

Adsorption of meloxicam on porous calcium silicate: Characterization and tablet formulation

Sameer Sharma 1, Praveen Sher 1, Shraddha Badve 1, Atmaram P Pawar 1,✉
PMCID: PMC2750609  PMID: 16408863

Abstract

The purpose of the present study was characterization of microparticles obtained by adsorption of poorly water soluble drug, meloxicam, on a porous silicate carrier Florite RE (FLR) and development of a tablet formulation using these microparticles, with improved drug dissolution properties. The study also reveals the use of FLR as a pharmaceutical excipient. Meloxicam was adsorbed on the FLR in 2 proportions (1∶1 and 1∶3), by fast evaporation of solvent from drug solution containing dispersed FLR. Drug adsorbed FLR microparticles were evaluated for surface topography, thermal analysis, X-ray diffraction properties, infrared spectrum, residual solvent, micromeritic properties, drug content, solubility, and dissolution studies. Microparticles showed bulk density in the range of 0.10 to 0.12 g/cm3. Dissolution of drug from microparticles containing 1∶3, drug∶FLR ratio was faster than microparticles containing 1∶1, drug∶FLR ratio. These microparticles were used for formulating directly compressible tablets. Prepared tablets were compared with a commercial tablet. All the prepared tablets showed acceptable mechanical properties. Disintegration time of prepared tablets was in the range of 18 to 38 seconds, and drug dissolution was much faster in both acidic and basic medium from prepared tablets as compared with commercial tablet. The results suggest that FLR provides a large surface area for drug adsorption and also that a reduction in crystallinity of drug occurs. Increase in surface area and reduction in drug crystallinity result in improved drug dissolution from microparticles.

Keywords: Florite RE, meloxicam, adsorption, microparticles, dissolution

Full Text

The Full Text of this article is available as a PDF (292.2 KB).

References

  • 1.Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–420. doi: 10.1023/A:1016212804288. [DOI] [PubMed] [Google Scholar]
  • 2.Meriani F, Coceani N, Sirotti C, Voinovich D, Grassi M. In vitro nimesulide absorption from different formulations. J Pharm Sci. 2004;93:540–552. doi: 10.1002/jps.10555. [DOI] [PubMed] [Google Scholar]
  • 3.Perrut M, Jung J, Leboeuf F. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes Part I. Micronization of neat particles. Int J Pharm. 2005;288:3–10. doi: 10.1016/j.ijpharm.2004.09.007. [DOI] [PubMed] [Google Scholar]
  • 4.Kinoshita M, Baba K, Nagayasu A, et al. Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. J Pharm Sci. 2002;91:362–370. doi: 10.1002/jps.10026. [DOI] [PubMed] [Google Scholar]
  • 5.Ambike AA, Mahadik KR, Paradkar A. Stability study of amorphous valdecoxib. Int J Pharm. 2004;282:151–162. doi: 10.1016/j.ijpharm.2004.06.009. [DOI] [PubMed] [Google Scholar]
  • 6.Chowdary KPR, Hymavathi R. Enhancement of dissolution rate of meloxicam. Ind J Pharm Sci. 2001;63:150–154. [Google Scholar]
  • 7.Smirnova I, Suttiruengwong S, Seiler M, Arlt W. Dissolution rate enhancement by adsorption of poorly soluble drugs on hydrophilic silica aerogels. Pharm Dev Technol. 2004;9:443–452. doi: 10.1081/PDT-200035804. [DOI] [PubMed] [Google Scholar]
  • 8.Streubel A, Siepmann J, Bodmeier R. Floating matrix tablet based on low density foam powder: effects of formulation and processing parameters on drug release. Eur J Pharm Sci. 2003;18:37–45. doi: 10.1016/S0928-0987(02)00223-3. [DOI] [PubMed] [Google Scholar]
  • 9.Yuasa H, Takashima Y, Kanaya Y. Studies on the development of intragastric floating and sustained release preparation. I. Application of calcium silicate as a floating carrier. Chem Pharm Bull (Tokyo) 1996;44:1361–1366. [Google Scholar]
  • 10.Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density foam powder. Int J Pharm. 2002;241:279–292. doi: 10.1016/S0378-5173(02)00241-7. [DOI] [PubMed] [Google Scholar]
  • 11.Ito Y, Arai H, Uchino K, Iwasaki K, Shibata N, Takada K. Effect of adsorbents on the absorption of lansoprazole with surfactant. Int J Pharm. 2005;289:69–77. doi: 10.1016/j.ijpharm.2004.10.010. [DOI] [PubMed] [Google Scholar]
  • 12.Salis A, Sanjust E, Solinas V, Monduzzi M. Characterization of Accurel MP 1004 polypropylene powder and its use as a support for lipase immobilization. J Mol Cat B Enz. 2003;24–25:75–82. doi: 10.1016/S1381-1177(03)00112-7. [DOI] [Google Scholar]
  • 13.Byrne RS, Deasy PB. Use of commercial porous ceramic particles for sustained drug delivery. Int J Pharm. 2002;246:61–73. doi: 10.1016/S0378-5173(02)00357-5. [DOI] [PubMed] [Google Scholar]
  • 14.Yuasa H, Asahi D, Takashima Y, Kanaya Y, Shinozawa K. Application of calcium silicate for medicinal preparation. I. Solid preparation adsorbing an oily medicine to calcium silicate. Chem Pharm Bull (Tokyo) 1994;42:2327–2331. doi: 10.1248/cpb.42.2327. [DOI] [PubMed] [Google Scholar]
  • 15.Yuasa H, Akutagawa M, Hashizume T, Kanaya Y. Studies on internal structure of tablets. VI. Stress dispersion in tablets by excipients. Chem Pharm Bull (Tokyo) 1996;44:378–382. doi: 10.1248/cpb.44.378. [DOI] [PubMed] [Google Scholar]
  • 16.Kinoshita M, Baba K, Nagayasu A, et al. Highly stabilized amorphous 3-bis(4-methoxyphenyl)methylene-2-indolinone (TAS-301) in melt-adsorbed products with silicate compounds. Drug Dev Ind Pharm. 2003;29:523–529. doi: 10.1081/DDC-120018641. [DOI] [PubMed] [Google Scholar]
  • 17.Jackson RL, Jason MD. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2000. pp. 713–714. [Google Scholar]
  • 18.Naidu NB, Chowdary KP, Murthy KV, Satyanarayana V, Hayman AR, Becket G. Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. J Pharm Biomed Anal. 2004;35:75–86. doi: 10.1016/j.jpba.2004.01.003. [DOI] [PubMed] [Google Scholar]
  • 19.Ghorab MM, Abdel-Salem HM, El-Sayad MA, Mekhel MM. Tablet formulation containing meloxicam and β-cyclodextrin: mechanical characterization and bioavailability evaluation. AAPS PharmSciTech. 2004;5:E59–E59. doi: 10.1208/pt050459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Seedher N, Bhatia S. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech. 2003;4:E33–E33. doi: 10.1208/pt040333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Cantera RG, Leza MG, Bachiller CM. Solid phases of tenoxicam. J Pharm Sci. 2002;91:2240–2251. doi: 10.1002/jps.10207. [DOI] [PubMed] [Google Scholar]
  • 22.International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.ICH Harmonised Tripartite Guideline. Impurities: guideline for residual solvents Q3C. Geneva, Switzerland: ICH; 1997.
  • 23.Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123–133. doi: 10.1016/S0928-0987(01)00095-1. [DOI] [PubMed] [Google Scholar]
  • 24.Charumanee S, Okonoki S, Sirithunyalug J. Improvement of the dissolution rate of piroxicam by surface solid dispersion. CMU J. 2004;3:77–84. [Google Scholar]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES